Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
This trial investigates the comparative effectiveness of two beta-blocker drugs, carvedilol and metoprolol succinate, in adults with heart failure with reduced ejection fraction HFrEF who have an implantable cardioverter defibrillator ICD. The study aims to provide clear data on which medication better reduces the risk of ICD therapy, cardiovascular hospitalizations, or cardiovascular death. It is a prospective, multicenter, randomized clinical trial enrolling 2,000 participants across 100 U.S. sites, including an 18-month feasibility phase. Participants currently taking metoprolol succinate will be randomized to either continue this treatment or switch to carvedilol at an equivalent dose. Both groups will have their doses adjusted to the maximum tolerated level as per the study protocol. The feasibility phase will evaluate recruitment, safety, adherence, and retention, while the full study will follow participants for up to three years, assessing clinical outcomes and quality of life. During the study, participants will undergo regular assessments including ICD device checks, laboratory tests, imaging, and surveys on quality of life and anxiety related to ICD shocks. Data collected will include cardiovascular events, healthcare use, medication adherence, and patient-reported outcomes measured at baseline and throughout the follow-up. The trial will also analyze results by patient subgroups such as age, sex, race, heart failure type, and ICD type to better understand treatment responses.
Actively Recruiting
Researchers are studying Medicare beneficiaries with Lumbar Spinal Stenosis LSS and Neurogenic Claudication NC to compare outcomes after two different procedures MILD Percutaneous Image-Guided Lumbar Decompression and Interspinous Process Decompression IPD. This observational study tracks patients treated since January 1, 2017, evaluating the rates of surgical and minimally invasive interventions as well as any harms related to these procedures over 24 months. The study uses Medicare claims data and does not require prior patient consent or IRB oversight. The study includes two groups of patients those who received the MILD procedure, involving partial decompression under image guidance by removing tissue and bone at the affected spinal level, and those who underwent IPD, a device-based decompression technique. Both groups are observed through Medicare data for two years after their initial procedure to assess the need for further surgeries or interventions and to monitor for any complications. Participants are followed for 24 months after their index procedure using Medicare claims data. Researchers monitor the rates of harms associated with the initial treatment and the frequency of additional surgical or minimally invasive interventions. Since this is an observational study, data collection relies on existing Medicare records without direct patient involvement, and the study will continue enrolling patients until the sponsor stops it.
Actively Recruiting
Researchers are evaluating the effects of taking olaparib for one year compared to two years, with or without the addition of bevacizumab, in patients with stage III or IV ovarian cancer that has specific genetic mutations BRCA 12 or a deficiency in homologous recombination. This phase III trial aims to determine if shorter treatment with olaparib is not worse than longer treatment and to study survival, disease progression, toxicity, and other outcomes. The study also explores genetic markers that might predict treatment response. Participants are randomly assigned to one of two groups. In the first group, patients take olaparib orally twice daily for up to two years and may receive bevacizumab intravenously every 21 days for up to one year. In the second group, patients receive olaparib twice daily for up to one year and may also receive bevacizumab on the same schedule. Both groups undergo blood sample collection and imaging scans such as CT or MRI during the study treatment period. After finishing treatment, participants are followed up every three months for two years and then every six months for another three years to monitor health and disease status. Researchers assess progression-free survival based on tumor scans and survival over up to five years. Side effects, including risks of certain blood disorders and secondary cancers, are tracked. The total participation duration may extend over several years, including treatment and long-term follow-up.